Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENO DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENO DIP.
HYPAQUE-CYSTO vs RENO-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
RENO-DIP (dipyridamole) is a platelet aggregation inhibitor that inhibits adenosine deaminase and phosphodiesterase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and blocks adenosine reuptake, resulting in vasodilation and inhibition of platelet aggregation.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Hypertension: initial 10 mg orally once daily, titrate to 40 mg once daily. Heart failure: initial 2.5 mg orally twice daily, titrate to 20 mg twice daily as tolerated.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily renal excretion of unchanged drug (70%) via glomerular filtration and active tubular secretion; 20% excreted as metabolites in urine; 10% eliminated in feces via biliary secretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent